MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
22nd Century Group Total Liabilities 2011-2026 | XXII
Annual Total Liabilities 22nd Century Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.53 M | 17.7 M | 35.9 M | 18.7 M | 9.88 M | 7.58 M | 6.9 M | 6.02 M | 4.31 M | 3.31 M | 6.64 M | 6.73 M | 4.76 M | 8.78 M | 3.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.9 M | 3.31 M | 9.95 M |
Quarterly Total Liabilities 22nd Century Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.3 M | 16.8 M | 17.8 M | 17.7 M | 22.7 M | 25 M | 36.2 M | 35.9 M | 50.4 M | 52.4 M | 42.8 M | 18.7 M | 21.1 M | 20 M | 8.51 M | 9.88 M | 7.44 M | 9.8 M | 7.19 M | 7.58 M | 7.58 M | 7.58 M | 7.58 M | 6.9 M | 6.55 M | 8.23 M | 6.9 M | 6.02 M | 6.02 M | 6.02 M | 6.02 M | 4.31 M | 4.31 M | 4.31 M | 3.48 M | 3.31 M | 3.31 M | 3.31 M | 3.31 M | 6.64 M | 6.57 M | 6.57 M | 6.57 M | 6.73 M | 6.73 M | 6.73 M | 6.73 M | 4.76 M | 4.76 M | 4.76 M | 4.76 M | 8.78 M | 8.78 M | 8.78 M | 8.78 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 52.4 M | 3.31 M | 11.3 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
6.06 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Exelixis
EXEL
|
683 M | $ 48.7 | - | $ 13.2 B | USA |
 |
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
123 M | $ 2.55 | - | $ 71.1 M | USA |
 |
Genmab A/S
GMAB
|
2.02 B | $ 27.89 | - | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
2.2 M | $ 0.89 | - | $ 830 K | USA |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 8.41 | - | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
13.7 M | $ 2.5 | - | $ 168 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
3.03 B | $ 76.85 | - | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 95.26 | - | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
163 M | $ 86.26 | - | $ 7.29 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
111 M | $ 232.55 | - | $ 4.25 B | USA |
 |
INmune Bio
INMB
|
8.83 M | $ 1.52 | - | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
283 M | $ 42.14 | - | $ 3.63 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 21.48 | - | $ 3.56 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
528 M | $ 110.08 | - | $ 5.53 B | USA |
 |
MannKind Corporation
MNKD
|
843 M | $ 3.56 | - | $ 1.09 B | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
768 M | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.35 | - | $ 5.51 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | Canada |
 |
Matinas BioPharma Holdings
MTNB
|
2.38 M | $ 0.68 | - | $ 3.72 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Nanobiotix S.A.
NBTX
|
152 M | $ 41.86 | - | $ 286 B | France |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.17 | - | $ 3.08 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
7.24 M | - | 10.36 % | $ 9.8 M | USA |